All In Biotech

Drug Trial Radar · NCT04129502

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

354

Actual

Start

Jan 10, 2020

Primary completion

Sep 22, 2026

Study completion Sep 22, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Oct 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group. Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.

Conditions

  • Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Interventions

  • TAK-788Drug

    TAK-788 capsule

  • PemetrexedDrug

    Pemetrexed IV infusion

  • CisplatinDrug

    Cisplatin IV infusion

  • CarboplatinDrug

    Carboplatin IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) as Assessed by Blinded Independent Review Committee (IRC) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: Up to approximately 40 months after the first participant is randomized

Locations

134 sites in 24 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Long Beach, California

  • University of California Irvine

    Orange, California

  • Stanford University

    Palo Alto, California

  • AdventHealth

    Orlando, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Maryland Greenebaum Cancer Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center - 330 Brookline Ave

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Sarah Cannon Cancer Center

    Nashville, Tennessee

  • University of Virginia Health System

    Charlottesville, Virginia

  • GenesisCare North Shore

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia

  • Klinik Floridsdorf

    Vienna, Austria

  • Cliniques Universitaires Saint-Luc

    Brussels, Brussels Capital, Belgium

  • Grand Hopital de Charleroi asbl

    Charleroi, Hainaut, Belgium

  • AZ Sint-Lucas

    Aalst, Oost-Vlaanderen, Belgium

  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • William Osler Health System

    Brampton, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Hopital Du Sacre Coeur de Montreal

    Montreal, Quebec, Canada

  • Beijing Cancer Hospital - PPDS

    Beijing, China

  • Beijing Chest Hospital, Capital Medical Univerity

    Beijing, China

  • Icahn School of Medicine at Mount Sinai

    Beijing, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Harbin Medical University Tumor Hospital

    Harbin, China

  • Shanghai East Hospital

    Shanghai, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Beijing Cancer Hospital - PPDS

    Beijing, Beijing Municipality, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • CHU de Grenoble

    Grenoble, France

  • Hopital Nord AP-HM

    Marseille, France

  • CRLC Val d'Aurelle - Paul Lamarque

    Montpellier, France

  • Hopital Tenon

    Paris, France

  • Nouvel Hopital Civil

    Strasbourg, France

  • Hopital Larrey

    Toulouse, France

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.